Bladder cancer
NEW --- Molecular diagnostics in the era of targeted therapies for mUCa

Aisha (70 years old)

Aisha, 70 years old, organises art workshops for underprivileged children, spreading joy and creativity in their lives. Unfortunately, she was diagnosed with MIBC, for which she received 4 cycles of neoadjuvant gemcitabine + cisplatin before RC 6 months ago.

Assessment summary:

  • ECOG PS: 1
  • Medical history: Hashimoto’s thyroiditis, rheumatoid arthritis
  • TURBT at initial diagnosis: minimal pT2 UCa cN0M0
  • Pathological review RC specimen: ypT2 ypN+ (3/18), lymphatic and vascular invasion, negative surgical margins

A recent CT scan showed new bilateral pulmonary nodes.

  • Pathological review of pulmonary node biopsy: confirmed a UCa metastasis

Her oncologist suggests testing FGFR3 alterations for further treatment decisions.

An FFPE tissue sample of the metastatic biopsy is readily available for molecular testing.

Which of the following options would you choose for testing FGFR3 alterations in this patient?